In Brief: Glaxo Wellcome's 3TC
Glaxo Wellcome's 3TC: Tradename is Epivir (lamivudine). The nucleoside analog's NDAs (20-564 for tablets and 20-596 for oral solution) for treatment of HIV infection are scheduled for a Nov. 6 review by FDA's Antiviral Drugs Advisory Committee ("The Pink Sheet" Oct. 2, T&G-1). On Nov. 7, the committee will review Roche's Invirase (saquinivir) NDA (20-628) for HIV infection. Confirmatory trials of Bristol-Myers Squibb's Zerit (stavudine) will be reviewed on Nov. 8. The meeting will begin at 8:30 a.m. Nov. 6-7. On Nov. 8, the meeting will be open from 8 a.m. to 12:30 p.m., with the afternoon session closed. The meeting will be held at the Quality Hotel, 8727 Colesville Rd. in Silver Spring, Md...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth